Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Epistemonikos ID: e84140a7e08b2c2194abd75f31538ceb10686ceb
First added on: Mar 27, 2025